Compare Inovio Pharmaceuticals Inc (INO) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nucor Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Nucor Corporation trades at $272.01 (market cap $61.93B). The key difference: Nucor Corporation is far larger — about 788.4× Inovio Pharmaceuticals Inc's market cap, and Nucor Corporation pays a 0.82% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NUE | |
|---|---|---|
Market Cap | $78.55M | $61.93B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $274.74 |
52-Week Low | $0.66 | $131.78 |
Enterprise Value | $49.56M | $66.34B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Nucor (NUE) trades at $269.50, down 1.86% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings with EPS of $4.84 beating estimates of $4.46, driven by record steel mill shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections indicating $36.1B revenue and improved margins. Analyst consensus remains positive with 59% buy ratings and a $279.63 price target, representing 3.8% upside potential.
Nucor presents a compelling investment case with earnings momentum, favorable analyst sentiment, and technical strength. Key opportunities include continued demand recovery and operational efficiency gains. However, risks include cyclical steel industry exposure, tariff policy uncertainties, and declining operating cash flow trends from 2022 peaks. The stock offers moderate upside to consensus targets but faces macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
